Press release +

Prothea Technologies™ is pleased to announce that Dr Adam Marshall, Consultant Physician in Respiratory Medicine at the Royal Infirmary of Edinburgh, UK and Principal Investigator of the Precision Lung clinical study (ISRCTN15093468), will present the results during AABIP 2026, the 9th Annual Conference of the American Association for Bronchology and Interventional Pulmonology. The conference will take place from 20-22 August in Denver, Colorado. Prothea is proud to sponsor the conference and looks forward to connecting with doctors and industry partners at Booth 06!

The single-centre feasibility study prospectively enrolled 20 participants undergoing clinically indicated bronchoscopy for suspected lung malignancy. The Investigational System combined a single-use 1.9 mm-diameter Eyes on Target Imaging & Access Catheter with KronoScan™ Label-free Molecular Imaging.  The principal end points were Safety, Procedural Success and change in Molecular Signature¹ at a malignant lesion.

The Precision Lung study was co-sponsored by the University of Edinburgh and NHS Lothian.

The Prothea Imaging system is in development and, at the date of this release, none of its component products are cleared for use in the United States or any other country. In readiness of the Prothea Imaging System launch in 2027 Prothea would welcome further discussions with independent distributors.

For further information, please contact:

Dr. Anne Moore, COO
Email: [email protected]

About Prothea

Prothea Technologies is a private medical technology company developing a novel image-guided therapy and a vision of lung cancer biopsy and treatment in a single hospital visit.

Lung cancer is the third most common form of cancer in the U.S. and annually claims more lives than breast, prostate and colon cancer combined. Screening programmes aim to facilitate the early detection of suspicious lesions, but delivering value from these initiatives present significant challenges for hospitals already grappling with low biopsy yields and false negatives, as well as surgical costs and post-surgical complications.

Prothea Technologies, a spin-out company from the Universities of Edinburgh and Bath, in-licensed several patents from these institutions as part of a Series A financing in 2024. Prothea’s novel bronchoscopy system is initially focused on patients requiring a biopsy, with abnormal lung lesions per CT scan. The technology combines innovative microscopic optical fibres, next generation fluorescence imaging and biopsy instruments to deliver adjacent image capture and tissue characterisation at the molecular level.

A laser Ablation System is in development for the treatment of lesions immediately following visualisation and biopsy. The integration of these two systems (real-time imaging and ablation) will streamline biopsy and treatment into a single hospital visit, reducing time-to-treat from weeks to minutes, thereby relieving hospital pressures and improving patient outcomes.

The Prothea Imaging System, combining a single-use Eyes on Target Imaging & Access Catheter with KronoScan™ Label-free Molecular Imaging and the Ablation System, are in development and are not currently cleared for use in any country.

The Company’s clinical pipeline also includes a well-advanced program supported by Wellcome, for the early identification of specific lung infections in intensive care patients, enabling earlier selection of optimal drug therapy.

¹Measured with Fluorescence Lifetime Imaging Microscopy (FLIM) – change characterised by areas of reduced fluorescence lifetime and lower fluorescence intensity.